INTRAVENTRICULAR CHEMOTHERAPY FOR PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) NEUROBLASTOMA (NB) (SIOP 2026) - Oct 23, 2026 - Abstract #Shift 02 - 209; Pres time: Sep 17, 2026; Location: Exhibition Area; "Intraventricular chemotherapy using intra-Ommaya (IO) administration of thiotepa, topotecan, and etoposide has demonstrated safety and tolerability in children with recurrent CNS tumors...Systemic therapies, including lorlatinib, DFMO, and anti-GD2 antibodies, were permitted during and between IO chemotherapy cycles... Serial IO chemotherapy was feasible and well tolerated with manageable myelosuppression and may provide durable CNS disease control when used as an adjuvant strategy following CSI for CNS NB."
Clinical • Brain Cancer • CNS Disorders • CNS Tumor • Hematological Disorders • Neuroblastoma • Neutropenia • Solid Tumor • Thrombocytopenia • MYCN
|
|
Wei Wei; Brian Kushner; Ellen Basu; Fiorella Iglesias Cardenas; Shakeel Modak; Kim Kramer
|